Quote:

---

we will see how that spike in sp holds up (With JNCE)

---

JNCE closed at 4.27 low of day, close to the high 4.25 the day the news was released. So almost back to where it started and the chart is looking bearish. There are people on ST that short these partnership spikes, because this seems to happen a lot. I believe the biggest issue is many partnership deals ultimately are not very good for original company. Also, as NP said, they will not be given leronlimab away, too many people have worked too hard and invested too much money, to give up leronlimab in the type of deal that BP would love to have.

I don't believe Gilead would allow cydy to get mono approval, it takes away too much market share for them When it becomes obvious leronlimab is getting approved for mono, they will step-in. Right now with a 150M market cap, they probably are still comfortable waiting just a little longer. The delays in the BLA and the mTNBC trial have played into their hands, keeping the MC suppressed. But with so many positive developments, I feel that is getting ready to change, if we can get the MC up, they will start sweating.